Faron Pharmaceuticals Oy Stock
€2.00
Your prediction
Faron Pharmaceuticals Oy Stock
Pros and Cons of Faron Pharmaceuticals Oy in the next few years
Pros
Cons
Performance of Faron Pharmaceuticals Oy vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Faron Pharmaceuticals Oy | -3.240% | - | - | - | - | - | - |
| Larimar Therapeutics Inc. | 0.000% | 3.311% | 5.405% | -47.119% | -16.129% | 6.849% | -84.369% |
| Vaxart Inc. | -0.640% | -0.285% | -15.152% | -51.473% | -58.457% | -72.387% | -95.556% |
| Achieve Life Sciences Inc. | -3.050% | -4.442% | -1.363% | -4.556% | 11.641% | 64.463% | -35.806% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Faron Pharmaceuticals, operating within the Biotechnology & Medical Research sector, presents a financial picture that raises concerns for potential investors. The company’s financial statements reflect significant operational challenges, along with a troubling history of revenue generation and profitability. With mounting losses and a precarious balance sheet, assessing Faron’s financial health requires a close examination of its assets, liabilities, cash flows, income statements, and pricing valuation strategies.
Market Capitalization and Target Price: Faron's market capitalization stands at approximately $178 million, which can indicate healthy interest from investors. The Wall Street target price of $3.16 suggests a potential for upside, assuming the company can navigate its financial difficulties effectively.
Strong Cash Flow from Financing Activities: Despite facing negative operating cash flows, the positive net cash flow from financing activities, roughly $23.98 million in 2023, shows that Faron can still attract capital. This influx of cash provides some liquidity that may support future operational needs or research and development (R&D) efforts.